HOME >> BIOLOGY >> NEWS
Brown scientists uncover inner workings of rare eye cells

PROVIDENCE, RI A Brown University team has found that a protein called melanopsin plays a key role in the inner workings of mysterious, spidery cells in the eye called intrinsically photosensitive retinal ganglion cells, or ipRGCs.

Melanopsin, they found, absorbs light and triggers a biochemical cascade that allows the cells to signal the brain about brightness. Through these signals, ipRGCs synchronize the body's daily rhythms to the rising and setting of the sun. This circadian rhythm controls alertness, sleep, hormone production, body temperature and organ function.

Brown researchers, led by neuroscientist David Berson, announced the discovery of ipRGCs in 2002. Their work was astonishing: Rods and cones aren't the only light-sensitive eye cells.

Like rods and cones, ipRGCs turn light energy into electrical signals. But while rods and cones aid sight by detecting objects, colors and movement, ipRGCs gauge overall light intensity. Numbering only about 1,000 to 2,000 out of millions of eyes cells, ipRGCs are different in another way: They have a direct link to brain, sending a message to the tiny region that controls the body clock about how light or dark the environment is. The cells are also responsible for narrowing the pupil of the eye.

"It's a general brightness detection system in the eye," said Berson, the Sidney A. Fox and Dorothea Doctors Fox Professor of Ophthalmology and Visual Sciences. "What we've done now is provide more details about how this system works."

The research, published in the current issue of Nature, provides the first evidence that melanopsin is a functional sensory photopigment. In other words, this protein absorbs light and sets off a chain of chemical reactions in a cell that triggers an electrical response. The study also showed that melanopsin plays this role in ganglion-cell photoreceptors, helping them send a powerful signal to the brain that it is day or night.

The team made
'"/>

Contact: Wendy Lawton
Wendy_Lawton@brown.edu
401-863-1862
Brown University
26-Jan-2005


Page: 1 2

Related biology news :

1. Brown rot shrivels prune production in California
2. Brown cancer biologists identify major player in cell growth
3. Bones in motion: Brown scientists to create new 3-D X-ray system
4. Brown team finds crucial protein role in deadly prion spread
5. Genomic variation easier to identify with UCSD/Brown software
6. Brown scientists map structure of DNA-doctoring protein complex
7. Brown and OTS will jointly manage new ILTER network secretariat
8. Brownfields may turn green with help from Michigan State research
9. NIH grants $11 million to Brown University for cancer research
10. Prions rapidly remodel good protein into bad, Brown study shows
11. Brown-Harvard team solves mobile DNAs surgical sleight-of-hand

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Brown scientists uncover inner workings rare eye cells

(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: